PureTech Health PLC (PRTC) - Total Liabilities
Based on the latest financial reports, PureTech Health PLC (PRTC) has total liabilities worth $229.03 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
PureTech Health PLC - Total Liabilities Trend (2012–2025)
This chart illustrates how PureTech Health PLC's total liabilities have evolved over time, based on quarterly financial data. See how liquid is PureTech Health PLC's working capital to evaluate short-term liquidity relative to the company's equity base.
PureTech Health PLC Competitors by Total Liabilities
The table below lists competitors of PureTech Health PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gorilla Technology Group Inc.
NASDAQ:GRRR
|
USA | $75.33 Million |
|
Jay Mart Public Company Limited
BK:JMART
|
Thailand | ฿23.37 Billion |
|
Crescent Capital BDC Inc
NASDAQ:CCAP
|
USA | $916.10 Million |
|
Apex International Co Ltd
TW:4927
|
Taiwan | NT$13.95 Billion |
|
Universal Logistics Holdings Inc
NASDAQ:ULH
|
USA | $1.24 Billion |
|
Apartment Investment and Management Co
NYSE:AIV
|
USA | $727.94 Million |
|
AQUILA PART PROD COM
RO:AQ
|
Romania | RON907.82 Million |
|
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A
SHE:002864
|
China | CN¥721.64 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down PureTech Health PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of PureTech Health PLC.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.59 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.73 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PureTech Health PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PureTech Health PLC (2012–2025)
The table below shows the annual total liabilities of PureTech Health PLC from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $229.03 Million | +17.63% |
| 2024-12-31 | $194.70 Million | -17.41% |
| 2023-12-31 | $235.74 Million | +52.03% |
| 2022-12-31 | $155.06 Million | -57.15% |
| 2021-12-31 | $361.86 Million | +7.55% |
| 2020-12-31 | $336.45 Million | +15.71% |
| 2019-12-31 | $290.78 Million | +5.82% |
| 2018-12-31 | $274.79 Million | -0.38% |
| 2017-12-31 | $275.85 Million | +33.69% |
| 2016-12-31 | $206.34 Million | +26.82% |
| 2015-12-31 | $162.70 Million | +72.46% |
| 2014-12-31 | $94.34 Million | +280.51% |
| 2013-12-31 | $24.79 Million | +10.00% |
| 2012-12-31 | $22.54 Million | -- |
About PureTech Health PLC
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The co… Read more